15.6C
Delhi
Tuesday, January 19, 2021

Serum Institute pauses Covid vax trials in India

- Advertisement -

covishield1New Delhi, Sep 10 (IANS) The Serum Institute of India (SII), which was conducting the India trials for the coronavirus vaccine being developed by Oxford University, on Thursday paused the clinical trials of the vaccine in India.

In a statement, the Serum Institute of India said: “We are reviewing the situation and pausing India trials till AstraZeneca restarts the trials. We are following DCGI’s instructions and will not be able to comment further on trials.”

The declaration by the Pune-based vaccine manufacturer came a day after the Drug Control General of India (DCGI), V.G. Somani, issued a show-cause notice to them asking for an explanation as to why the institute decided to go ahead with the clinical trial of Covid-19 vaccine candidate while doubts about patient safety are yet unclear.

READ ALSO:  India should aim to become world's largest coal exporter: PM

The notice was issued in the wake of an advert incident where one of the participants in the UK reported a suspected severe adverse reaction when administered a booster dose of Covishield, a vaccine candidate developed jointly by pharma giant AstraZeneca and University of Oxford, on Tuesday.

“Whereas, Serum Institute of India Pvt Ltd, Pune, till now has not informed the Central licensing authority regarding pausing the clinical trial carried out by AstraZeneca in other countries and also not submitted casualty analysis of the reported serious adverse event with the investigational vaccine for the continuation of phase 2 and 3 clinical trials of the subject vaccine in the country in light of the safety concerns,” the notice by DGCI read.

READ ALSO:  Ram Madhav reiterated India's claim to Aksai Chin as its own

The DGCI further asked the institute why the authority does not suspend the permission given to the SII for the clinical trials of Covishield.

“In view of the above, I, Dr V G Somani, Drugs Controller General of India and Central Licensing Authority hereby give you an opportunity to show cause as provided under rule 30 of the New Drugs and Clinical Trials Rules, 2019, why the permission granted to you August 2 shall not be suspended till patient safety is established,” the notice further said.

READ ALSO:  Anti-CAA protesters obstruct key highways in Bengal

SII is the partner of the University of Oxford’s Jenner Institute’s to conduct the vaccine trials. SII is currently progressing the second and third phase study of the vaccine candidate at 17 trial sites across India.

Source: IANS

India Updates
India Updates is an independent news & Information website. Follow us for regular updates on News and Information.

Follow Us On

Related News

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Trending Topics In India

Covid 19 India Updates

Trending News In India

Trending Showbiz

Trending Sports

Latest Trending News In India

Juhi Chawla on WhatsApp: When anything is free, your freedom is the price

Mumbai, Jan 18 (IANS) Juhi Chawla on Monday took a jibe at social networking platforms WhatsApp and Facebook at a time when millions of...

Arm-twisting tactics won’t work: Punjab CM again warns Centre

Chandigarh, Jan 18 (IANS) Condemning the NIA notices issued to several farmers and their supporters amid the anti-farm laws agitation, Punjab Chief Minister Amarinder...

‘Vaccine won’t kill you’: AIIMS Director allays fears

New Delhi, Jan 18 (IANS) AIIMS Director Randeep Guleria on Monday allayed apprehensions about the coronavirus vaccines and assured that the side-effects will not...

We will not quarrel, but celebrate R-Day: Farmer leader Rakesh Tikait

Ghazipur, Jan 18 (IANS) The farmers protesting against the new Central farm laws have announced a 'Tractor March' on Republic Day. On Monday, the...